Clinical Trials /

TRUEBEAM Stereotactic Body Radiotherapy for Localized Prostate Cancer

NCT04552509

Description:

The purpose of this study is to determine the effects of TrueBeam stereotactic body radiosurgery in patients with prostate cancer. The device is designed to concentrate large doses of radiation onto the tumor so that injury from radiation to the nearby normal tissue will be minimal. The purpose of this evaluation is to see if this treatment will help patients with your condition and to evaluate the effect of this treatment on your quality of life over time. Radiosurgery is a non-invasive treatment technique used to treat tumors. Despite the word "surgery" in the name, the technology does not remove the tumor with a surgical knife. Instead, a focused, high-intensity beam of radiation targets the tumor, while minimizing dose to surrounding normal healthy tissue.

Related Conditions:
  • Prostate Adenocarcinoma
Recruiting Status:

Recruiting

Phase:

N/A

Trial Eligibility

Document

Title

  • Brief Title: TRUEBEAM Stereotactic Body Radiotherapy for Localized Prostate Cancer
  • Official Title: Prospective Evaluation of TRUEBEAM Stereotactic Body Radiotherapy for Localized Prostate Cancer: Risk Stratified MonoTherapy Versus RADIOSURGERY Boost

Clinical Trial IDs

  • ORG STUDY ID: 790-17
  • NCT ID: NCT04552509

Conditions

  • Prostate Cancer

Purpose

The purpose of this study is to determine the effects of TrueBeam stereotactic body radiosurgery in patients with prostate cancer. The device is designed to concentrate large doses of radiation onto the tumor so that injury from radiation to the nearby normal tissue will be minimal. The purpose of this evaluation is to see if this treatment will help patients with your condition and to evaluate the effect of this treatment on your quality of life over time. Radiosurgery is a non-invasive treatment technique used to treat tumors. Despite the word "surgery" in the name, the technology does not remove the tumor with a surgical knife. Instead, a focused, high-intensity beam of radiation targets the tumor, while minimizing dose to surrounding normal healthy tissue.

Detailed Description

      1.0 BACKGROUND 1.1 Prostatic adenocarcinoma is one of the most common forms of malignancy in
      men. Every year over 200000 patients are diagnosed with prostate cancer in the United States.
      Treatment options for these patients include active surveillance, radical prostectomy,
      external beam radiation therapy, permanent source interstitial brachytherapy and high dose
      rate (HDR) brachytherapy.

      1.2 Each of these treatment options vary in regards to the logistics, anticipated outcomes,
      and potential side effects of therapy.

      1.3 High-dose rate (HDR) brachytherapy has been used in the treatment of prostate cancer
      since the 1980's with good results. Catheters are placed temporarily in the prostate, and
      then loaded with a high-dose Iridium-192 source, delivering a few fractions of very high-dose
      RT. Brachytherapy allows the delivery of conformal, high-dose radiotherapy to the prostate,
      with a rapid dose fall-off outside of the region. It also takes advantage of low alpha/beta
      ratio of prostate cancer by using a hypofractionated approach.

      1.4 The TrueBeam is a noninvasive radiosurgical system, capable of treating any part of the
      body from multiple targeting angles, creating a highly conformal three-dimensional
      radiosurgical treatment volume, guided by orthogonal X-ray-based targeting feedback, and
      delivering radiation by a highly collimated, robotically controlled linear accelerator. The
      TrueBeam system targets implanted fiducial markers with sub-millimeter set-up accuracy.

      1.5 From a dosimetry standpoint, TrueBeam Stereotactic radiosurgery is capable of producing a
      dose distribution comparable to that created by prostate HDR brachytherapy treatment, without
      the need for invasive transperineal catheters, anesthesia, or inpatient admission. It would
      therefore be possible to deliver the HDR boost portion of a patient's treatment in a
      non-invasive fashion. As such, the TrueBeam prostate dose fractionation schedule prescribed
      in this study is based upon prior published prostate HDR brachytherapy experience both as a
      monotherapy and as a boost to external beam radiation therapy in patients with higher risk
      disease. The therapeutic volume in this study will also be made to resemble prostate HDR
      brachytherapy therapeutic volume, with similar dose limitation objectives to the adjacent
      tissues, including the rectum, bladder and urethra. It is theorized that such an approach
      should result in similar cancer control rates while lowering overall morbidity and improving
      the patient's comfort and convenience.

      1.6 The feasibility of stereotactic body radiation therapy for treating localized prostate
      cancer was first described by King at Stanford University. Their phase I protocol delivered
      36.25Gy in 5 fractions of 7.25Gy. In a recent report of acute and 18-month late toxicity in
      26 "low-risk" patients, no patient experienced grade 3 or 4 acute or late toxicity, and only
      one patient experienced a grade 2 late morbidity (urethral stricture). Toxicity was less than
      that reported in MD Anderson's external beam dose escalation trial. Mean PSA 18 months after
      treatment was 0.22ng/ml. Naples Community Hospital reported a series of more than 70 low and
      intermediate risk patients treated with the SBRT. The prostate received 35 Gy in 5 fractions
      of 7 Gy each; acute toxicity was minimal. San Diego Cyberknife, which used a virtual HDR
      technique, reported a series of more than 124 low and intermediate risk patients treated. The
      prostate received 38Gy in 4 fractions of 9.5Gy each; acute toxicity was minimal.

      1.7 Another potential benefit of stereotactic body radiosurgery relative to HDR brachytherapy
      is possibly better preservation of potency, even if the radiation distribution is essentially
      identical between these modalities. This is so because needle trauma has been identified as a
      potentially significant contributory factor to erectile dysfunction with brachytherapy,
      including HDR-based monotherapy technique, presumably due to direct physical injury to the
      neurovascular bundle and/or bulb of the penis, particularly when greater than 13 needle
      insertions are performed. By comparison, stereotactic body radiosurgery is noninvasive, and
      so removes this particular erectile dysfunction risk factor.
    

Trial Arms

NameTypeDescriptionInterventions
ObservationOtherObservational study of patient efficacy and side effects

    Eligibility Criteria

            Inclusion Criteria
    
              1. Histologically proven prostate adenocarcinoma
    
                   -  Biopsy within 12 months of date of registration required except for patients who
                      already meet criteria for enrollment in the high risk arm of the protocol. For
                      these patients, repeat biopsy will be at the discretion of the treating
                      physician. In general, repeat biopsy is recommended for these patients, but is
                      not required if it will not affect the treating physician's management decisions
                      in regards to the care of the patient.
    
              2. Clinical Stage I-IV, MX-M0 (AJCC 6th Edition)
    
                   -  M-stage determined by physical exam, CT, MRI, or Bone Scan. Bone scan not
                      required for Monotherapy Risk Group patients unless clinical findings suggest
                      possible osseous metastases. Bone Scan and contrast CT of the abdomen should be
                      done patients in the Boost Risk Group patients.
    
              3. Prostate volume: ≤ 100 cc (recommended not required)
    
                   -  Determined using: volume = π/6 x length x height x width
    
                   -  Measurement from CT or ultrasound ≤90 days prior to registration.
    
              4. ECOG performance status 0-1
    
              5. Completion of patient questionnaires in section 4.7.
    
              6. Consent signed
    
            Exclusion Criteria:
    
              1. Prior prostatectomy or cryotherapy of the prostate
    
              2. Prior radiotherapy to the prostate or lower pelvis
    
              3. Implanted hardware or other material that would prohibit appropriate treatment
                 planning or treatment delivery, in the investigator's opinion.
          
    Maximum Eligible Age:N/A
    Minimum Eligible Age:N/A
    Eligible Gender:Male
    Healthy Volunteers:No

    Primary Outcome Measures

    Measure:Local control
    Time Frame:5 years
    Safety Issue:
    Description:Rate of disease recurrence locally

    Details

    Phase:N/A
    Primary Purpose:Interventional
    Overall Status:Recruiting
    Lead Sponsor:Linda Chan, MD

    Last Updated

    September 11, 2020